Merck KGaA: Millipore deal was worth it

Merck KGaA's $6 billion purchase of Massachusetts-based biotechnology equipment supplier Millipore is "worth every euro," CEO Karl-Ludwig Kley told shareholders at his company's annual general meeting today. In February, the German drugmaker swooped in with an offer for Millipore, beating out Thermo Fisher. Including debt, the deal was valued at $7.2 billion.  Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.